Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
AssigneeNorthwestern University
InventorsRichard B. Silverman, Hoang V. Le, Rima L. McLeod, Dustin D. Hawker
Life of this patent
Estimating the term…
Abstract
Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human γ-aminobutyric aminotransferase (GABA-AT).
Claims11
A method for treating a subject infected with an Apicomplexan parasite, the method comprising administering to the subject an effective amount of a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite, wherein the compound has a formula:
- wherein:
- R1 and R2 are hydrogen, halo, or a C1-C6 alkyl which may be straight or branched and optionally may be substituted at one or more positions with halo;
- or
- R1 and R2 together form a C1-C6 alkenyl group optionally substituted at one or more positions with halo or C1-C6 haloalkyl;
- and
- R3 is hydrogen or halo.
Dependencies are inferred from the claim text.